Trial Profile

A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Danavorexton (Primary)
Indications Idiopathic hypersomnia
Focus Adverse reactions
Sponsors Takeda Oncology

Most Recent Events

26 Apr 2022 Results assessing safety and tolerability of a single 9-hour intravenous infusion of TAK-925 112 mg compared with placebo in adults with idiopathic hypersomnia presented at the 74th Annual Meeting of the American Academy of Neurology 2022
08 Dec 2020 Status changed from active, no longer recruiting to completed.
09 Nov 2020 Planned End Date changed from 17 Jul 2021 to 30 Nov 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com